Sorbitol-fermenting Escherichia coli O157, Scotland by Pollock, Kevin G.J. et al.
LETTERS
Sorbitol-fermenting 
Escherichia coli 
O157, Scotland 
To the Editor: Verotoxin-pro-
ducing  Escherichia coli (VTEC) of 
serogroup O157 causes severe gas-
trointestinal and renal illness; clinical 
signs may be mild diarrhea, hemor-
rhagic colitis, or hemolytic uremic 
syndrome (HUS). Typically, 10%–
15% of reported VTEC infections 
quickly progress to HUS (1). Sorb-
itol-fermenting (SF)–O157 strains 
have emerged in continental Europe 
(2,3). Some evidence suggests that 
SF-O157 is more frequently associ-
ated with HUS than are non-sorbitol–
fermenting strains (3–6). SF-O157 
shows increased adherence to colonic 
epithelial cells and may in turn cause 
a more potent inﬂ  ammatory host re-
sponse, resulting in a higher risk 
for HUS (4). The potentially greater 
virulence of SF-O157 requires ur-
gent identiﬁ  cation of its reservoir(s) 
and vehicle(s) of infection, as well as 
determination of genetic or other pre-
disposing factors for infection with 
this strain. To understand whether the 
host pathophysiologic responses to 
SF-O157 and non–SF-O157 strains 
differ, we analyzed a cohort of chil-
dren with HUS who were infected 
with E. coli O157.
During April and May 2006, 
Health Protection Scotland (HPS) 
identiﬁ  ed 18 cases of verotoxin-pro-
ducing SF-O157 infection in Scot-
land, 13 of which were associated 
with a nursery. HUS developed in 8 of 
the 18 patients; those with thrombotic 
microangiopathy were admitted to the 
renal unit of a specialist pediatric hos-
pital, which immediately reports cases 
of HUS to HPS as part of national 
surveillance (7). To test the hypoth-
esis that SF-O157 was more virulent 
than non–SF-O157, we performed an 
age-matched, nested case–case study 
of HUS case-patients and analyzed 
host clinical markers, treatment, and 
outcomes from SF-O157 and non–
SF-O157 cases in 2006. Clinical ques-
tionnaires, patient information sheets, 
and consent forms were completed by 
clinicians for each case-patient and re-
turned to HPS; data were entered into 
a database in Epi Info version 6 (Cen-
ters for Disease Control and Preven-
tion, Atlanta, GA, USA).
Statistical analysis by t test 
showed that nadirs for serum albumin 
were signiﬁ  cantly higher for children 
with SF-O157 HUS (p = 0.03; Table) 
than for children with non–SF-O157 
HUS and that children with SF-O157 
HUS had signiﬁ  cantly more sessions 
of hemodialysis than did children with 
non–SF-O157 HUS (p = 0.01; Table). 
All case-patients were oligoanuric; the 
2 groups did not differ with respect to 
this parameter. Initial signs and symp-
toms were similar for both sets of pa-
tients, i.e., classic VTEC symptoms of 
bloody diarrhea and abdominal pain. 
This  ﬁ   nding is in acccordance with 
those of other studies of SF-O157 
outbreaks, which also noted signs and 
symptoms compatible with VTEC-
associated gastroenteritis (5,6).
Our study highlights a number of 
lessons. Medical practitioners rarely 
have the opportunity to recognize pa-
tients at such an appreciable and pre-
dictable risk of progressing rapidly to 
anuric renal failure as they do when 
they see children with early O157 in-
fection. Failure to appreciate the po-
tential gravity of O157 infection and 
the possible development of HUS may 
result in avoidable illness and even 
death. Our investigation of the pre-
hospital management of SF-O157 and 
non–SF-O157 in this cohort found no 
difference in pharmacologic interven-
tion or duration of delay in admission 
to hospital.
Our study has limitations. A num-
ber of patients in the cohort were pre-
scribed antimicrobial drugs and/or 
antimotility drugs or were sent home 
from the local hospital without hospi-
tal admission or further monitoring; 
such actions potentially exacerbate 
clinical outcomes (1,8). We recog-
nize that comparison of the SF-O157 
outbreak strain with non–SF-O157 
strains (some of which caused sporad-
ic cases) may be a potential confound-
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Table. Characteristics of patients infected with non–SF-O157 versus SF-O157 
Escherichia coli, Scotland, 2006* 
Characteristic
SF-O157,
n = 8
Non–SF-O157, 
n = 19  p value 
Age, y r SEM  5.4 r 1.4  5.1 r 0.9 
Sign or symptom, no. (%) patients 
 Diarrhea  8 19
  Bloody diarrhea  6 (75)  14 (74)  0.79
  Abdominal pain  6 (75)  13 (68)  0.13
  Fever  1 (12)  4 (21)  0.73
  Neurologic involvement  2 (25)  4 (21)  0.82
Clinical parameter, mean r SEM 
 Anuria,  d  11.7 r 2.7  7.9 r 1.4  0.20
 Leukocyte  count,  u10
9/L 26.4 r 2.1  36.4 r 10.1  0.34
  C-reactive protein, mg/L  65.6 r 27.1  93.4 r 23.1  0.31
 Serum  albumin,  g/L  32.4 r 7.0  23.2 r 1.0  0.03
  Lactate dehydrogenase, IU/L  2,774 r 280  2,556 r 324  0.68
  Hospital stay, d  17.9 r 3.7  16.1 r 2.9  0.71
Treatment, mean no. sessions r SEM 
 Peritoneal  dialysis  13.4 r 2.3  7.4 r 1.9  0.07
 Hemodialysis  20.5 r 3.5  9.3 r 1.3  0.01
Outcomes, 1 y follow-up, no.  n = 6  n = 19 
  Full recovery, no. patients  6 17
  Clinical sequelae, no. patients  0 2†
*SF, sorbitol-fermenting. 
†1 with hypertension, 1 with abdominal pain/vomiting. LETTERS
ing factor in the analysis. However, 
recently published work has indicated 
no statistically signiﬁ  cant differences 
in the verotoxin proteins encoded by 
SF-O157 or non–SF-O157 strains or 
in their level of toxicity (9). Other 
virulence factors may contribute to in-
creased likelihood of HUS (4).
Our data suggest that infection 
with SF-O157 results in less severe 
colitis than does the more common 
non–SF-O157 infection. Less severe 
colitis could result in a lower risk for 
renal disease because less verotoxin 
would be translocated into the blood-
stream and bound to the kidneys. 
However, patients infected with SF-
O157 had anuria for longer periods 
and consequently had longer sessions 
of peritoneal and hemodialysis. Al-
though unknown bacterial or host in-
ﬂ  ammatory cytokines may contribute 
to enhanced disease progression, this 
observation is surprising and requires 
further investigation. Additional re-
search is needed to learn more about 
the virulence of SF-O157 strains and 
establish other host factors that con-
tribute to disease progression.
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Co-infection with 
Dengue Virus and 
Pandemic (H1N1) 
2009 Virus
To the Editor: Dengue is a mos-
quito-borne viral infection caused by 4 
related dengue viruses. Each of these 
viruses is capable of causing classic 
dengue fever or dengue hemorrhagic 
fever (DHF), but may also cause non-
speciﬁ  c febrile illnesses. As a result, 
dengue is often difﬁ  cult to diagnose 
clinically, especially because peak 
dengue season often coincides with 
that of other common febrile illnesses 
in tropical regions (1). Concurrent out-
breaks of inﬂ  uenza and dengue have 
been reported (2,3); this circumstance 
often leads to delayed recognition of 
the presence of one or other disease in 
the community.
In April 2009, a new strain of in-
ﬂ  uenza A virus known as pandemic 
(H1N1) 2009 virus was ﬁ  rst detected 
in the United States (4). Pandemic 
(H1N1) 2009 infections were ﬁ  rst 
detected in Puerto Rico in June 2009, 
and 59 deaths caused by the virus have 
been conﬁ  rmed to date. This inﬂ  uenza 
outbreak coincided with the typical 
dengue season in Puerto Rico, which 
led to diagnostic difﬁ  culties; both in-
fections disproportionately affected 
young persons, who often had similar, 
nonspeciﬁ  c symptoms.
We describe a case of laboratory-
conﬁ  rmed co-infection of dengue virus 
and pandemic (H1N1) 2009, and dis-
cuss the difﬁ  culties in distinguishing 
the 2 illnesses clinically. A 33-year-old 
woman (healthcare worker) in Ponce, 
Puerto Rico, sought treatment at an 
emergency department of a hospital 
in the southern part of the island with 
a 3-day history of febrile illness. Her 
symptoms began with throat irritation 
and earache; subsequently, cough, 
fever, and headache developed. She 
reported palpitations and generalized 
malaise but no other symptoms. The 
patient had no notable medical his-
882  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 5, May 2010